GAITHERSBURG, Md., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced it will host its 4th annual Investor and Analyst Meeting, Tuesday, October 11, 2016 from 9:00 a.m. – 11:00 a.m. ET in New York, NY.
Senior management will conduct a series of presentations to update analysts and investors on the Company’s ongoing clinical development programs. In addition, a key opinion leader will provide a clinical perspective on respiratory syncytial virus (RSV) disease.
Novavax expects to announce data from its pivotal Phase 3 trial of the RSV F Vaccine in older adults in the third quarter of 2016.
For additional information and registration, please email firstname.lastname@example.org or call 443-213-0506.
A live webcast of the presentations can be accessed under the “Investors”/ “Events” section of the Novavax website at novavax.com. Please allow extra time prior to the webcast to visit the site and download the streaming media software required to listen to the Internet broadcast. The webcast and a replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com. The event will be archived on the company's website for 90 days.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company’s website, novavax.com.
Novavax, Inc.Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations
Russo Partners, LLCDavid SchullTodd Davenport, Ph.D.